维多利亚和维克多:以事件为驱动的经验教训,用于将受益者指导纳入实践,并减少HFrEF的剩余风险
Kalliopi Keramida1,2, Francesca Musella3, Magdy Abdelhamid4
1Department of Cardiology, General Anticancer Oncological Hospital Agios Savvas, Alexandras Avenue 171, Athens, 111522, Greece. keramidakalliopi@hotmail.com.
Heart failure reviews
|December 11, 2025
概括
一种新药Vericiguat针对慢性心力衰竭中氧化物信号受损的降低射出率心力衰竭 (HFrEF). 它刺激可溶性瓜尼酸环酶恢复循环瓜诺辛单酸盐信号传输,解决HFrEF治疗中未满足的需求.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 慢性心力衰竭与减少喷射分数 (HFrEF) 呈现出显著的发病率和死亡率,尽管目前的指导方针导向医学治疗 (GDMT).
- 氧化 (NO) 信号受损,可溶性酸环酶 (sGC) 响应能力降低,循环氨酸单酸 (cGMP) 降低是心力衰竭进展的关键病理机制.
- 现有的HFrEF治疗方法,包括ACEI/ARB/RNAI,β-阻断剂,MRA和SGLT2is,无法完全解决这些潜在的信号缺陷.
研究的目的:
- 为了研究一种口服sGC刺激剂的 vericiguat在HFrEF患者中的治疗潜力.
- 评估 vericiguat恢复受损的NO-sGC-cGMP信号通路的能力,这些信号通路与HFrEF病变有关.
- 探索新的药理学目标,以改善慢性心力衰竭的结果.
主要方法:
- 给药的 vericiguat,一个口服可溶性瓜尼酸环酶 (sGC) 刺激剂.
- 评估 vericiguat的作用机制,包括sGC对内源性氧化 (NO) 的敏感化和酶的直接刺激.
- 评估循环单酸 (cGMP) 信号在相关细胞通路的下游恢复.
主要成果:
- 韦里西瓜特有效地使可溶性酸环酶 (sGC) 对内源性氧化 (NO) 敏感.
- 药物直接刺激sGC活动,独立于NO水平.
- 在血管光滑肌和心肌细胞中观察到cGMP信号的恢复,这表明HFrEF的潜在益处.
结论:
- 韦瑞西瓜特通过准NO-sGC-cGMP通路,为HFrEF提供了一种新的治疗方法.
- 它的双重作用机制为解决残留风险和改善慢性心力衰竭患者的治疗结果提供了一个有希望的策略.
- 需要进一步的临床研究来确定HFrEF群体中 vericiguat的疗效和安全性.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:25Mitral Regurgitation III: Medical Management
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...